LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

Search

Ligand Pharmaceuticals Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

105.94 2.26

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

104.29

Max

106.33

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-11M

-42M

Pardavimai

2.5M

45M

P/E

Sektoriaus vid.

47.016

51.198

Pelnas, tenkantis vienai akcijai

1.33

Pelno marža

-93.643

Darbuotojai

68

EBITDA

-11M

-41M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+43.18% upside

Dividendai

By Dow Jones

Kitas uždarbis

2025-08-05

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-46M

2B

Ankstesnė atidarymo kaina

103.68

Ankstesnė uždarymo kaina

105.94

Naujienos nuotaikos

By Acuity

13%

87%

14 / 380 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Strong Bearish Evidence

Ligand Pharmaceuticals Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-06-06 14:31; UTC

Uždarbis

New York State Retirement Fund Posts 5.84% Annual Investment Return

2025-06-06 20:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2025-06-06 20:50; UTC

Rinkos pokalbiai

Auto & Transport Roundup: Market Talk

2025-06-06 20:33; UTC

Uždarbis

These Stocks Moved the Most Today: Tesla, DJT, Broadcom, Circle, Lululemon, Docusign, Quanex, Braze, and More -- Barrons.com

2025-06-06 19:36; UTC

Rinkos pokalbiai

Oil Futures Post Solid Weekly Gains -- Market Talk

2025-06-06 19:28; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures Rise on Demand Expectations -- Market Talk

2025-06-06 18:46; UTC

Rinkos pokalbiai

Gold Faced With Tariff Uncertainty Offset by ETF Withdrawals -- Market Talk

2025-06-06 18:02; UTC

Rinkos pokalbiai

U.S. Oil Rig Count Continues to Decline -- Market Talk

2025-06-06 16:35; UTC

Uždarbis

These Stocks Are Moving the Most Today: Tesla, DJT, Broadcom, Circle, Lululemon, Docusign, Quanex, Braze, and More -- Barrons.com

2025-06-06 16:34; UTC

Uždarbis

These Stocks Are Moving the Most Today: Tesla, DJT, Broadcom, Circle, Lululemon, Docusign, Quanex, Braze, and More -- Barrons.com

2025-06-06 16:21; UTC

Rinkos pokalbiai

Canadian Unemployment Set to Continue Feel Trade War Pressures -- Market Talk

2025-06-06 16:20; UTC

Rinkos pokalbiai

Auto & Transport Roundup: Market Talk

2025-06-06 16:20; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2025-06-06 16:20; UTC

Rinkos pokalbiai

Health Care Roundup: Market Talk

2025-06-06 16:15; UTC

Rinkos pokalbiai

Global Commodities Roundup: Market Talk

2025-06-06 16:07; UTC

Rinkos pokalbiai

Market Talk Roundup: Latest on U.S. Politics

2025-06-06 16:07; UTC

Rinkos pokalbiai

Base Metal Prices Slide But Copper Set to End Week Higher -- Market Talk

2025-06-06 15:53; UTC

Rinkos pokalbiai

Mexican Inflation Seen Rising in May -- Market Talk

2025-06-06 15:36; UTC

Rinkos pokalbiai

Dollar's Boost From U.S. Jobs Data Could Be Limited -- Market Talk

2025-06-06 15:36; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2025-06-06 15:33; UTC

Rinkos pokalbiai

Gold Futures Slide After Jobs Data Surprises to Upside -- Market Talk

2025-06-06 15:16; UTC

Rinkos pokalbiai

Tesla Showing Signs of Weakness in Key Regions -- Market Talk

2025-06-06 15:05; UTC

Rinkos pokalbiai

Silver at its Highest In Nearly 15 Years -- Market Talk

2025-06-06 14:35; UTC

Rinkos pokalbiai

Weakening Canadian Job Market Seen Keeping BoC in Easing Mode -- Market Talk

2025-06-06 14:28; UTC

Rinkos pokalbiai

Bitcoin Rises After Above-Forecast U.S. Jobs Data -- Market Talk

2025-06-06 14:28; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2025-06-06 14:28; UTC

Rinkos pokalbiai

Canada's Job Market Weakens But Not Seen Collapsing -- Market Talk

2025-06-06 14:15; UTC

Rinkos pokalbiai

Oil Rises on U.S.-China Talks Optimism -- Market Talk

2025-06-06 14:12; UTC

Uždarbis

Palantir and Super Micro Computer Stocks Rise as Broadcom Posts Strong AI Revenue -- Barrons.com

2025-06-06 14:09; UTC

Uždarbis

Broadcom, the $1 Trillion Stock You Shouldn't Ignore, Makes AI Investment Case -- Barrons.com

Akcijų palyginimas

Kainos pokytis

Ligand Pharmaceuticals Inc Prognozė

Kainos tikslas

By TipRanks

43.18% į viršų

12 mėnesių prognozė

Vidutinis 149.17 USD  43.18%

Aukščiausias 160 USD

Žemiausias 135 USD

Remiantis 7 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Ligand Pharmaceuticals Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

7 ratings

7

Pirkti

0

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

102.5 / 109.24Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Strong Bearish Evidence

Vidutinės trukmės periodas

Very Strong Bearish Evidence

Ilgalaikis periodas

Weak Bullish Evidence

Rinkos nuotaikos

By Acuity

14 / 380 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Labai stiprus bulių rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Ligand Pharmaceuticals Inc

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida.